Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06538116 | A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | PHASE2 | ACTIVE NOT_RECRUITING | 300 | — | — | Aug 26, 2024 | May 1, 2026 | Dec 17, 2025 | 64 | United States, Japan |
iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance.
| Arm | Type | Description |
|---|---|---|
| Mevidalen (high dose) | EXPERIMENTAL | Mevidalen high dose administered orally. |
| Mevidalen (low dose) | EXPERIMENTAL | Mevidalen low dose administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| Mevidalen | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * Have MMSE score of 13 to 24. * Have eligibile plasma P-tau or historical evidence of AD pathology. * Have a relia...